XBiotech is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases. Co. has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. An area of medical focus for Co. are therapies that block a substance naturally produced by body, known as interleukin-1 alpha, that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. Co.'s product development includes: 514G3 program, which is for the indication of S. aureus Bacteremia; and other programs, which are for the indications of C. difficile, Influenza and Herpes Varicella Zoster (Chickenpox). The XBIT stock yearly return is shown above.
The yearly return on the XBIT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XBIT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|